ASH 2025 | Second-line therapy outcomes in CML after frontline second-generation TKI failure
Fadi Haddad
• 7 Dec 2025
Fadi Haddad, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses outcomes of patients with chronic myeloid leukemia (CML) who required second-line therapy after frontline second-generation tyrosine kinase inhibitors (TKIs). Dr Haddad highlights that most patients achieved meaningful responses after switching treatment, with particularly favorable outcomes seen with newer-generation TKIs. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
